Radium Ra-223
- Generic Name
- Radium Ra-223
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 54
- Registration Number
- NCT05924672
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- GenesisCare USA
- Registration Number
- NCT05771896
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 36
- Registration Number
- NCT05383079
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
- Conditions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 122
- Registration Number
- NCT04995614
- Locations
- 🇳🇱
Catharina ziekenhuis, Eindhoven, Netherlands
🇳🇱Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands
🇳🇱Rijnstate ziekenhuis, Arnhem, Netherlands
Radium-223 in Biochemically Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT04206319
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 64
- Registration Number
- NCT04037358
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 738
- Registration Number
- NCT03574571
- Locations
- 🇺🇸
Millennium Physicians, Houston, Texas, United States
🇪🇸Vall d'Hebron Institute of Oncology (VHIO) (Data Collection Only), Barcelona, Spain
🇪🇸Clinic de Barcelona, Barcelona, Spain
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2023-05-30
- Target Recruit Count
- 70
- Registration Number
- NCT03230734
- Locations
- 🇮🇹
U.O. Oncologia PO Vito Fazzi, Lecce, LE, Italy
🇮🇹UO Oncologia Medica, IRST IRCCS, Meldola, FC, Italy
🇮🇹IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03208712
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.